Dec 01, 2020 / 05:35PM GMT
Liisa Ann Bayko - Evercore ISI Institutional Equities, Research Division - Research Analyst
Hi, Daniel. How are you?
Daniel Tassé,DBV Technologies S.A.-CEO&Director
I'm great, Liisa. How are you?
Liisa Ann Bayko - Evercore ISI Institutional Equities, Research Division - Research Analyst
I'm good. So I want to welcome Daniel Tassé, Chief Executive Officer of DBV Technologies. DBV is working in the area of peanut allergy. So a lot of enthusiasm there. Companies had its ups and downs, and I think they're working their way back up right now. So I think we're excited to get into the details. But maybe first, just to set the stage, Daniel, you can tell us a little bit more about DBV.
Daniel Tassé,DBV Technologies S.A.-CEO&Director
Yes. DBV is a company that is exploring the fact that the human skin is actually a pretty powerful immune organ, something that is not always well understood,
DBV Technologies SA at Evercore ISI HealthCONx Conference Transcript
Dec 01, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers